Xcision Medical Systems has obtained the US Food and Drug Administration (FDA) 510(k) clearance for its GammaPod Stereotactic Radiotherapy System.

GammaPod is a non-invasive external beam system that is optimised for partial breast treatments with stereotactic radiotherapy, which delivers high doses in single or multiple large fractions.

After set up on the GammaPod, the patient is rotated by a robotic system from standing to the prone position to ensure better sparing of critical structures such as the heart, when compared to other radiation therapy techniques used for breast cancer.

Xcision Medical Systems founder and CEO Cedric Yu said: “Every aspect of the GammaPod system has been optimised to non-invasively treat targets within the breast using highly conformal dose distributions.

“We set out to design a solution in a real-world clinical setting that would be more convenient for patients.”

“We set out to design a solution in a real-world clinical setting that would be more convenient for patients, more efficient for hospitals and clinicians, and more cost-effective for our healthcare system.”

The stereotactic radiotherapy system is set to be studied at various GammaPod research consortium clinical trial sites such as the University of Maryland and UT Southwestern Medical Center.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Through these trials, the firm aims to validate the use of ultra-accelerated stereotactic partial breast irradiation to provide equivalent or superior local control with less toxicity.

The trials will be led by University of Maryland School of Medicine radiation oncology assistant professor Elizabeth Nichols, who expects that GammaPod could potentially identify a subset of patients not requiring surgery.